• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Enable Injections

Enable Injections, Sanofi obtain approval for on-body myeloma therapy in Japan

October 22, 2026 By Conor Hale

A patient wears the Enable Injections disc-shaped Enfuse device on their stomach.

After obtaining U.S. and European approvals this summer, Enable Injections has claimed its first regulatory green light in Japan for its enFuse wearable drug delivery technology. The country’s Ministry of Health, Labour and Welfare approved Sanofi’s push-button CirCLIQ Injector for administering a subcutaneous formulation of Sarclisa (isatuximab-irfc), a monoclonal antibody for multiple myeloma used in […]

Filed Under: Auto-injectors, Drug-Device Combinations Tagged With: Cancer, Enable Injections, Japan, oncology, sanofi

Inside the first-of-its-kind Enable Injections enFuse drug delivery wearable

July 21, 2026 By Jim Hammerand

A patient wears the Enable Injections disc-shaped Enfuse device on their stomach.

When Sanofi won FDA approval in July 2026 for the first anticancer treatment administered with an on-body injector (OBI), the Enable Injections enFuse platform made it possible. The enFuse OBI secured its initial combination product FDA approval in 2023 for adults with paroxysmal nocturnal hemoglobinuria, a rare blood disorder. That milestone made enFuse the “first purely mechanical, large-volume, on-body […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Technology Tagged With: Enable Injections

FDA approves Sanofi anticancer treatment delivered through Enable Injections on-body device

July 10, 2026 By Sean Whooley

A patient wears the Enable Injections disc-shaped Enfuse device on their stomach.

Sanofi announced today that the FDA approved the delivery of its Sarclisa anticancer therapy through the Enable Injections on-body device. Sarclisa (isatuximab-irfc) Escena in combination with standard-of-care regimens received clearance for the treatment of patients with multiple myeloma (MM) across all existing indications of the Sarclisa intravenous (IV) formulation. Approval makes it the first anticancer […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Immunotherapy, Oncology, Technology Tagged With: Enable Injections, FDA, sanofi

Enable Injections picks up $30M investment from Sanofi

January 6, 2026 By Sean Whooley

Enable Injections enFuse Empaveli Injector

Enable Injections announced today that it received a commitment from Sanofi for a $30 million investment to drive growth. The investment from the pharmaceutical giant aims to accelerate Enable’s manufacturing build-out. It follows the company’s 2024 announcement of plans to expand its Ohio manufacturing plant. Other uses for funds include strengthening supply chain capabilities and […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals Tagged With: Enable Injections, sanofi

Enable Injections wins CE mark for enFuse drug delivery device

March 25, 2025 By Sean Whooley

Enable Injections enFuse Empaveli Injector

Enable Injections announced today that it received CE mark approval for its EnFuse syringe transfer system for drug delivery. enFuse, an on-body delivery system, provides subcutaneous abdominal bolus administration of drug or biologic products in accordance with the drug product requirements. The mechanical, wearable device can deliver large volumes of small molecule and biologic medications […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Regulatory/Compliance Tagged With: Enable Injections

Enable Injections inks deal to develop Parkinson’s therapy for delivery with EnFuse

May 15, 2024 By Sean Whooley

Enable Injections enFuse Empaveli Injector

Enable Injections announced today that it partnered with Serina Therapeutics to develop therapeutics for the enFuse delivery system. The companies aim to develop and commercialize SER-252 (POZ-apomorphine) in combination with enFuse to treat Parkinson’s disease. This deal builds upon a recent agreement that allows Roche to obtain a worldwide, exclusive license to develop and commercialize […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Neurological, Pharmaceuticals Tagged With: Enable Injections, Serina Therapeutics

Enable Injections, Roche expand enFuse delivery partnership

May 7, 2024 By Sean Whooley

Enable Injections enFuse Empaveli Injector

Enable Injections announced today that it expanded its collaboration with Roche to utilize its enFuse delivery technology in development programs. The partnership allows Roche to develop and apply Enable Injections’ expertise and enFuse technology to specific development programs. Through the collaboration, Roche can obtain a worldwide, exclusive license to develop and commercialize combinations of enFuse […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Enable Injections, Roche

Enable Injections to expand manufacturing facility to support drug delivery device production

February 14, 2024 By Sean Whooley

Enable Injections enFuse Empaveli Injector

Enable Injections announced today that it plans to expand its manufacturing operations with a new, large-scale facility in Ohio. In addition to the expansion in Springdale, Ohio, the company plans to enhance its corporate headquarters in Evendale, Ohio. Both facilities, nearby one another, sit just outside of Cincinnati. Enable Injections plans for its new 90,000-square-foot […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured Tagged With: Enable Injections

Enable Injections promotes COO from within

February 7, 2024 By Sean Whooley

Enable Injections David Kroekel COO

Wearable drug delivery technology maker Enable Injections announced today that it named David Kroekel as its new COO. Cincinnati-based Enable develops the enFuse platform, whichallows hands-free, hidden needle drug delivery of up to 25 mL. Its simple design enables flexibility for at-home self-administration or in-clinic use. The FDA cleared the system for the delivery of […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Personnel Tagged With: Enable Injections, Personnel Moves

Enable Injections adds finance veteran to its board

November 7, 2023 By Sean Whooley

Vickie Capps Enable Injections NuVasive

Enable Injections announced today that it appointed Vickie Capps to its board of directors as the head of the audit committee. Capps joins the wearable drug delivery system maker with plenty of experience in finance and executive leadership. She also brings extensive board experience, including currently serving on the board of orthopedic company NuVasive. Other […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Personnel Tagged With: Enable Injections, Personnel Moves

  • Page 1
  • Page 2
  • Page 3
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS